CME/CE - PACE-CME

Episodes 113-119 of 119

MinuteCE®
Role of CETP inhibitors in cardiovascular risk reduction - Will lessons from the past lead to future success?
1.00 credit 3 episodes
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
- Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma
- Roxana Mehran, MD
1.00 credit 3 episodes
Unmet needs in lowering LDL-c
Unmet needs in lowering LDL-c
MinuteCE®
Unmet needs in lowering LDL-c
1.00 program credit
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
1.00 program credit
New insights on CETP inhibition from genetic research and clinical trials
New insights on CETP inhibition from genetic research and clinical trials
MinuteCE®
New insights on CETP inhibition from genetic research and clinical trials
1.00 program credit
- Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma
1.00 program credit
Hypertrophic cardiomyopathy: What are the concerns?
Hypertrophic cardiomyopathy: What are the concerns?
MinuteCE®
Hypertrophic cardiomyopathy: What are the concerns?
1.00 program credit
- Antonis Pantazis, MD
1.00 program credit
Diagnostic challenges for symptomatic obstructive HCM
Diagnostic challenges for symptomatic obstructive HCM
MinuteCE®
Diagnostic challenges for symptomatic obstructive HCM
1.00 program credit
- Pablo García-Pavía, MD, PhD
1.00 program credit
MinuteCE®
Seeing the forest through the trees - Diagnosing and treating hypertrophic cardiomyopathy
1.00 credit 3 episodes
- Antonis Pantazis, MD
- Pablo García-Pavía, MD, PhD
- Carolyn Ho, MD
1.00 credit 3 episodes
Improving quality of life in patients with HCM
Improving quality of life in patients with HCM
MinuteCE®
Improving quality of life in patients with HCM
1.00 program credit
- Carolyn Ho, MD
1.00 program credit

Previous
1
2
…
6
7
8
Next

8/6